How Does Bristol-Myers Squibb’s Oncology Drugs Portfolio Compare To Its Peers?

By Trefis Team, Contributor Bristol-Myers Squibb’s (NYSE:BMY) oncology drugs business is its largest therapeutic area, and it will likely grow in mid-single-digits from about $10.3 billion in 2018 to $12.4 billion in 2021, according to Trefis estimates. This growth will likely be driven by higher sales of Opdivo. In this … …read more

Read more here::